These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 28667064)

  • 61. Should dialysis modalities be designed to remove specific uremic toxins?
    Baurmeister U; Vienken J; Ward RA
    Semin Dial; 2009; 22(4):454-7. PubMed ID: 19709001
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction.
    Fujii H; Goto S; Fukagawa M
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29772660
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Uremic Toxins and Blood Purification: A Review of Current Evidence and Future Perspectives.
    Magnani S; Atti M
    Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33808345
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Uremia and chronic kidney disease: the role of the gut microflora and therapies with pro- and prebiotics.
    Vitetta L; Gobe G
    Mol Nutr Food Res; 2013 May; 57(5):824-32. PubMed ID: 23450842
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Update on the pharmacokinetics and redox properties of protein-bound uremic toxins.
    Watanabe H; Miyamoto Y; Otagiri M; Maruyama T
    J Pharm Sci; 2011 Sep; 100(9):3682-95. PubMed ID: 21538353
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.
    Prokopienko AJ; Nolin TD
    Expert Rev Clin Pharmacol; 2018 Jan; 11(1):71-82. PubMed ID: 28905671
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Roles of organic anion transporters in the progression of chronic renal failure.
    Enomoto A; Niwa T
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S27-31. PubMed ID: 17976081
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Critical Appraisal of Limitations in the Current Definition/Classification of Uremic Toxins.
    Husain-Syed F; Vanholder R; Rosner MH; Kawanishi H; Sirich TL; Ronco C
    Blood Purif; 2023; 52(3):221-232. PubMed ID: 36513030
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Extracorporeal strategies for the removal of middle molecules.
    Winchester JF; Audia PF
    Semin Dial; 2006; 19(2):110-4. PubMed ID: 16551287
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A bench to bedside view of uremic toxins.
    Vanholder R; Baurmeister U; Brunet P; Cohen G; Glorieux G; Jankowski J;
    J Am Soc Nephrol; 2008 May; 19(5):863-70. PubMed ID: 18287557
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of Uremic Toxins in Early Vascular Ageing and Calcification.
    Kyriakidis NC; Cobo G; Dai L; Lindholm B; Stenvinkel P
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33401534
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Review of protein-bound toxins, possibility for blood purification therapy.
    Neirynck N; Glorieux G; Schepers E; Pletinck A; Dhondt A; Vanholder R
    Blood Purif; 2013; 35 Suppl 1():45-50. PubMed ID: 23466378
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tryptophan-Derived Uremic Toxins and Thrombosis in Chronic Kidney Disease.
    Addi T; Dou L; Burtey S
    Toxins (Basel); 2018 Oct; 10(10):. PubMed ID: 30322010
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The uremic toxin, indoxyl sulfate, signifies cardio-renal risk and intestinal-renal relationship].
    Kiss I
    Orv Hetil; 2011 Oct; 152(43):1724-30. PubMed ID: 21983398
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Uremic toxicity: present state of the art.
    Vanholder R; Argilés A; Baurmeister U; Brunet P; Clark W; Cohen G; De Deyn PP; Deppisch R; Descamps-Latscha B; Henle T; Jorres A; Massy ZA; Rodriguez M; Stegmayr B; Stenvinkel P; Wratten ML
    Int J Artif Organs; 2001 Oct; 24(10):695-725. PubMed ID: 11817319
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Exploring the uremic toxins using proteomic technologies.
    Schiffer E; Mischak H; Vanholder RC
    Contrib Nephrol; 2008; 160():159-171. PubMed ID: 18401168
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bioengineered implantation of megalin-expressing cells: a potential intracorporeal therapeutic model for uremic toxin protein clearance in renal failure.
    Saito A; Kazama JJ; Iino N; Cho K; Sato N; Yamazaki H; Oyama Y; Takeda T; Orlando RA; Shimizu F; Tabata Y; Gejyo F
    J Am Soc Nephrol; 2003 Aug; 14(8):2025-32. PubMed ID: 12874456
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Non-dialyzable uremic toxins and renal tubular cell damage in CKD patients: a systems biology approach.
    Asadi R; Shadpour P; Nakhaei A
    Eur J Med Res; 2024 Aug; 29(1):412. PubMed ID: 39123228
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of renal failure on drug transport and metabolism.
    Sun H; Frassetto L; Benet LZ
    Pharmacol Ther; 2006 Jan; 109(1-2):1-11. PubMed ID: 16085315
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of Chronic Kidney Disease and Uremic Toxins on Extracellular Vesicle Biology.
    Yaker L; Kamel S; Ausseil J; Boullier A
    Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33371311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.